Soligenix(SNGX) - 2025 Q4 - Annual Report

Drug Development and Clinical Trials - The company is developing HyBryte™, a novel photodynamic therapy for cutaneous T-cell lymphoma (CTCL), with patient enrollment for the second Phase 3 study (FLASH2) starting in December 2024 and top-line results anticipated in the second half of 2026[14]. - The first Phase 3 FLASH study demonstrated a statistically significant treatment response with 16% of patients achieving at least a 50% reduction in their index lesions compared to 4% in the placebo group[33]. - The company plans to expand the development of synthetic hypericin (SGX302) into psoriasis, following positive proof-of-concept results from a small Phase 1/2 pilot study[15]. - Dusquetide (SGX945) is being developed for the treatment of aphthous ulcers in Behçet's Disease, with a Phase 2 clinical trial planned based on previous validation of its biological activity[15]. - The Phase 3 trial of SGX942 for oral mucositis in head and neck cancer showed a 56% reduction in the median duration of severe oral mucositis from 18 days in the placebo group to 8 days in the treatment group[24]. - The confirmatory Phase 3 trial will enroll approximately 80 subjects and evaluate the efficacy and safety of HyBryte™ over 18 weeks[39]. - The ongoing Phase 3 study of HyBryte™ has enrolled 66 patients as of February 2026, with a planned interim analysis in Q2 2026[64]. - The Phase 2a trial of SGX302 for mild-to-moderate psoriasis showed a mean drop of approximately 50% in the Psoriasis Activity and Severity Index score over 18 weeks[74]. - SGX945 demonstrated a 40% improvement in the mean number of ulcers compared to placebo in a Phase 2a study, with a sustained 32% improvement at Week 8 after treatment cessation[85]. - SGX942 reduced the median duration of severe oral mucositis (SOM) by 50% from 18 days to 9 days in a Phase 2 study[98]. Market Potential - The potential worldwide market for HyBryte™ is estimated to exceed $250 million for the treatment of CTCL[66]. - The potential worldwide market for SGX302 is estimated to exceed $1 billion for the treatment of mild-to-moderate psoriasis[77]. - The global psoriasis treatment market was valued at approximately $15 billion in 2020 and is projected to reach as much as $40 billion by 2027[80]. - The potential worldwide market for SGX945 is estimated to exceed $200 million for the treatment of aphthous ulcers in Behçet's Disease (BD)[91]. - The potential worldwide market for SGX942 is estimated to exceed $500 million for the treatment of oral mucositis[109]. Regulatory Designations and Funding - HyBryte™ has received Orphan Drug and Fast Track designations from the FDA, providing market exclusivity and expedited review benefits[40]. - A $2.6 million Orphan Products Development grant was awarded to support expanded treatment evaluation for early-stage CTCL[46]. - The company has received government grant and contract funding to support its vaccine programs, including those targeting filoviruses and COVID-19[16]. - The company is pursuing additional government funding for its Specialized BioTherapeutics and Public Health Solutions programs through grants and contracts[23]. - A $9.4 million NIAID grant supported the development of thermo-stable ricin (RiVax®) and anthrax vaccines using ThermoVax® technology[115]. Technology and Innovation - The development of the heat stabilization platform technology, ThermoVax®, continues in combination with various vaccine programs, supported by U.S. government funding[23]. - ThermoVax® technology aims to eliminate the need for cold chain production and storage for Alum-adjuvanted vaccines, potentially reducing costs associated with refrigerated conditions[114]. - The thermostabilized RiVax® formulation enhances stability, allowing storage for at least 1 year at temperatures up to 40 degrees C (104 degrees F)[138]. - The second Phase 1b clinical trial of RiVax® indicated that the Alum-adjuvanted formulation induced greater ricin neutralizing antibody levels compared to the adjuvant-free version[137]. Competitive Landscape - The company faces competition from larger pharmaceutical and biotechnology companies with greater resources[187]. - There are currently no FDA approved therapies for front-line, early stage (I-IIA) CTCL, with existing treatments primarily managing symptoms[188]. - The only approved drug for oral mucositis in hematological cancer is palifermin, with no approved drugs for solid tumors[191]. - The only approved drug for Behçet's Disease (BD) is apremilast, which is associated with high costs and significant side effects[194]. Intellectual Property - The company holds several patents related to HyBryte™, including U.S. patent 8,629,302, expected to expire in September 2030[204]. - The company has Orphan Drug designations for HyBryte™ and SGX945, providing seven years of post-approval marketing exclusivity in the U.S.[205]. - SGX94 has composition of matter patents expiring between 2028 and 2034, protecting its unique mechanism of action[206]. - ThermoVax® is covered by U.S. patents expiring between 2028 and 2030, focusing on thermostable vaccine compositions[207]. Collaboration and Partnerships - The company is pursuing strategic alternatives, including merger/acquisition strategies, and to acquire or in-license new clinical-stage compounds for development[23]. - An agreement with SciClone provides access to clinical data for SGX942 in exchange for exclusive commercialization rights in China, Hong Kong, and Macau[183].